What the tablet’s documents cover
The adverse-reaction tables for Rybelsus® contain no entry for periods, bleeding or cycle length [1][2][3]. The reproductive information sits elsewhere, in the sections on pregnancy, breastfeeding, fertility and drug interactions.
| Topic | US label [1] | EU [2] and Canada [3] |
|---|---|---|
| Menstrual side effects | None listed | None listed |
| Contraception | No specific statement | EU: effective contraception required; Canada: contraception recommended |
| Pregnancy | Use only if benefit justifies the risk; stop at least 2 months before a planned pregnancy | Should not be used in pregnancy; stop at least 2 months before a planned pregnancy |
| Breastfeeding | Not recommended (SNAC in milk) | Should not be used (SNAC in milk) |
| Combined pill (ethinylestradiol and levonorgestrel) | No clinically significant change in levels | No clinically relevant change in levels |
Why the tablet has its own pregnancy rules
Two ingredients are at stake. Semaglutide stays in the body for about five weeks after the last tablet, which is why the labels set a 2-month gap before a planned pregnancy [1]. SNAC, the absorption enhancer that lets semaglutide pass through the stomach wall, also matters: in rats it crossed the placenta and, at high doses, lengthened pregnancy and increased stillbirths [1]. Canada notes that because semaglutide and SNAC have both shown developmental effects in animals, there may be an added risk when both are taken in pregnancy [3].
Breastfeeding follows the same logic. Semaglutide was not measurable in breast milk, but SNAC and its breakdown products were, and infants may clear SNAC more slowly than adults [1][3]. The US label therefore advises against breastfeeding on Rybelsus® and notes that semaglutide products without SNAC exist [1].
If you could become pregnant, these points are worth raising before a cycle change prompts the question: Europe’s leaflet says you have to use contraception while taking the tablets and that treatment should be changed if you become pregnant [2].
Fertility and the cycle: animal and human data
The effect of semaglutide on human fertility is unknown [2][3]. In female rats given semaglutide, the oestrous cycle (the rat equivalent of the menstrual cycle) became longer and slightly fewer eggs were released, at doses that also caused weight loss in the mothers [2][3]. Male fertility in rats was unaffected [2].
Two 2026 analyses of FDA adverse event reports looked at menstrual problems across GLP-1 medicines. In women aged 12 to 55, semaglutide was reported more often than expected with heavy menstrual bleeding, bleeding between periods, menstrual clots, infrequent periods and cycles without ovulation [4]. The second found semaglutide linked to more reports of polycystic ovary syndrome and menstrual abnormalities, while dulaglutide and tirzepatide showed lower reporting for several of these terms [5]. Neither separated tablets from injections. For semaglutide tablets alone, a 2024 analysis found 28 reproductive-system reports from 2019 to 2023, not significantly more than expected (reporting odds ratio 0.81) [7]. Reports like these can flag a pattern; they cannot tell you whether the medicine caused it.
Why a cycle might change
- Weight loss: MedlinePlus lists severe weight loss, and weight change of more than about 4.5 kg, among causes of irregular bleeding, and sudden large weight loss among causes of missed periods [8][9]. Rybelsus® lowers weight in many people, although the US monotherapy trial reported an average loss of 2.3 kg on 7 mg and 3.7 kg on 14 mg over 26 weeks, against 1.4 kg on placebo [1].
- Ovulation returning: in polycystic ovary syndrome, a 2026 scoping review of 25 mostly small studies of semaglutide reported more regular cycles in several of them, and warned that restored ovulation can lead to an unplanned pregnancy [6].
- Eating less: decreased appetite is a common reaction to the tablet, reported in 6% on 7 mg and 9% on 14 mg against 1% on placebo [1]. Very low body fat, heavy exercise and severe emotional distress are also listed causes of missed periods [9].
- Everything else: thyroid problems, fibroids or polyps, hormonal contraception, clotting disorders, perimenopause and pregnancy itself can all change bleeding [8][9].
The pill and the morning tablet
Studies with a combined pill containing ethinylestradiol and levonorgestrel found no meaningful change in hormone levels when taken with semaglutide tablets [1][2][3]. The questions that remain, such as what to do after vomiting or diarrhoea, are covered on our page about GLP-1 medicines and oral contraceptives rather than repeated here.
One tablet-specific point is routine. Rybelsus® is taken alone on an empty stomach, and the label asks you to wait at least 30 minutes before any other oral medicine [1]. If you take a pill in the morning, it belongs after that gap, which is worth agreeing with your prescriber so neither tablet is taken off schedule.
When bleeding needs a check
MedlinePlus describes abnormal uterine bleeding as bleeding that lasts longer than usual or comes at an unexpected time: spotting between periods, bleeding after sex, periods lasting more than 7 days or much heavier than normal, or any bleeding after menopause [8]. Very heavy bleeding includes passing large clots or soaking a pad or tampon every hour for 2 to 3 hours in a row, and losing a lot of blood over time can cause anaemia with tiredness [8]. Missing more than one period is also a reason to see a provider, starting with a pregnancy test [9].
Our periods, hot flashes and fatigue guide covers general cycle tracking; this page is limited to what is specific to Rybelsus®.
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.